Day: February 21, 2024

Positive Adjusted EBITDA* for Q4 2023 more than doubles from Q3 2023 to $5 million (Net Loss of $2.8 million) leading to a significant turnaround for the full year versus 2022 Record quarterly revenue of $23.5 million and annual revenue of $81.8 million Updated Phase 1 trial investigating sudocetaxel zendusortide in advanced ovarian cancer reaches key milestone with enrollment of first six patients Guidance for 2024 set to $87-90 million in annual revenue and a positive Adjusted EBITDA in the range of $13-15 million for the full year 2024MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...

2023 net income of $3.4 million Annual EBITDA1 of $34.6 million – $17.2 million returned to shareholders2 in 2023 Quarterly dividend of Cdn$0.03 per share declared, representing an 8.6% yield3 VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce financial results for the year and three months (“Q4-2023”) ended December 31, 2023. Dollar amounts in this news release are in U.S. dollars unless indicated otherwise. Amerigo’s annual financial results included net income of $3.4 million, earnings per share (“EPS”) of $0.02 and EBITDA1 of $34.6 million. In 2023, Amerigo returned $17.2 million to shareholders despite lower copper production levels due to historically significant Chilean weather events and a higher-than-normal...

Expects to Achieve the Lowest Record Net Loss and Cash Burn in Company History TROY, Mich., Feb. 21, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced preliminary unaudited financial results for the fourth fiscal quarter of 2023 and updates for its Ocean Deep/Golden Lake Business Park project. Fourth Quarter 2023 OutlookNet Loss in Q4 2023 is expected to be at a historical low of $750 thousand, compared to $2.1 million net loss in Q3 2023, and $58 million loss in Q4 2022. Loss from Operations is expected to decrease by 46% to a historical low of $2.5 million, compared to $4.6 million in Q3 2023 Gross Profit is expected to increase 105% to $1.9 million, compared to $1 million in...

Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of 1.03WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023. The company is also providing financial guidance for the full year 2024. Tony J. Hunt, Chief Executive Officer of Repligen said, “During the fourth quarter, we again saw order strength, driven by our Filtration and Analytics franchises and continued momentum from new modality accounts, which reflects the differentiated nature of our products in this market. We are pleased to report...

— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70, respectively —  — Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a), respectively — — Clinical trial ongoing for CTX211™, an allogeneic, hypoimmune, gene-edited, stem cell derived product candidate for the treatment of Type 1 Diabetes (T1D) —  — Strengthened balance sheet with $280 million registered direct offering, bringing current cash position to >$2.1 billion — ZUG, Switzerland and BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...

Consolidated revenues were $677.2 million, up 7.4% and up 6.0% on an organic constant currency (OCC) basis for the fourth quarter of 2023. Prior year results included storm-related revenue associated with Hurricane Ian, which negatively impacted OCC growth by 90 basis points. For the full year 2023, consolidated revenues were $2,681.4 million, up 7.4% and up 8.7% on an OCC basis.Income from continuing operations was $182.3 million, down 15.5% for the fourth quarter of 2023. Adjusted EBITDA, a non-GAAP measure, was $362.0 million, up 9.0%, and up 6.5% on an OCC basis. For the full year 2023, income from continuing operations was $768.4 million, down 26.3%, while adjusted EBITDA was $1,433.5 million, up 11.6%, and up 11.5% on an OCC basis.Diluted GAAP earnings per share from continuing operations (diluted EPS attributable to Verisk) were...

2023 consolidated earnings per diluted share of $2.24 Significant improvement in Avista Utilities earnings reflects the benefits of cost recovery and cost management 2024 consolidated earnings guidance initiated at $2.36 to $2.56 per diluted shareSPOKANE, Wash., Feb. 21, 2024 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) today announced financial results for 2023. Net income and earnings per diluted share for the fourth quarter and the year ended Dec. 31, 2023 (year-to-date) as compared to the respective periods of 2022 are presented in the table below (dollars in thousands, except per-share data):  Fourth Quarter     Year-to-Date    2023     2022     2023     2022  Net Income (Loss) by Business Segment:                      Avista Utilities $ 83,081     $ 52,660     $ 167,016     $ 117,901  AEL&P   3,248       3,253       8,937       7,545  Other   (2,194 )     22,043       (4,773 )     29,730  Total...